Arcutis Biotherapeutics, Inc. 4

Non-employee director Terrie Curran exercised 1,072 stock options at $7.51 and sold 1,072 Arcutis Biotherapeutics (ARQT) common shares at a weighted average price of $26.0376 on August 20, 2026.

On August 20, 2026, Terrie Curran, a non-employee director of Arcutis Biotherapeutics, Inc., exercised a stock option for 1,072 shares of common stock at an exercise price of $7.51 per share and immediately sold the same 1,072 shares in the open market at a weighted average price of $26.0376 per share, realizing an implied spread of roughly $18.53 per share. The option, which was fully vested and scheduled to expire on May 31, 2033, was exercisable in full one year after May 31, 2023, and this transaction reflects a classic exercise-and-sell for value rather than a net new purchase or sale changing Curran’s overall share count from this specific option grant. Following the transactions, Curran reported direct beneficial ownership of 23,526 shares of common stock, which, using the sale price as an indicative market value, represents an equity stake worth approximately $612,900. The sale price disclosure is based on a weighted average of multiple trades executed between $26.00 and $26.2228 per share, with the reporting person committing to provide detailed breakdowns upon request, indicating routine compliance and no unusual structuring in the trade execution.

Filing Facts

CIK

1787306

Ticker

ARQT

Form

4

Source Type

fda

Accession

0001628280-26-058648

Alert Tier

5